 This is a first-in-human, Phase 1, open-label, multicenter, dose escalation study designed to determine the safety and tolerability of repeated intratumoral injections of mRNA 2416 in patients with advanced relapsedrefractory solid tumor malignancies or lymphoma. The study will include 2 dosing periods: a Dose Escalation Period followed by an Expansion Period at the MTDRDE as determined by the Dose Escalation Period. 